iiinova — where your digital self keeps evolving

Fotios Barkas @fotiosbarkas.bsky.social · 08/01/2026

💡 Why it matters Risk- and benefit-based DSS tools may still add value - especially in #primarycare, where guideline gaps persist and #EHR-integrated solutions could scale impact.

100

Fotios Barkas @fotiosbarkas.bsky.social · 08/01/2026

🔍 What did we find? • No significant difference vs standard of care • But a favorable signal towards greater and earlier use of combination LLT (61.6% vs 50.6%) and therefore LDL-C target attainment • High usability & feasibility in routine practice

100

Fotios Barkas @fotiosbarkas.bsky.social · 08/01/2026

🔔 In case you missed it, check our recent publication from the #ZODIAC trial! 📊 1,139 ACS patients | 42 hospitals | UK, Italy & Spain We tested whether a personalized clinical hashtag#DSS estimating #CVD risk and benefit from different #LLT strategies could improve lipid management after ACS.

100

Fotios Barkas @fotiosbarkas.bsky.social · 10/10/2025

Webinar | 🗓️ 20/10/25, 18:00 (Zoom) Από τις Οδηγίες 2019 ➜ 2025: Τι αλλάζει στη διαχείριση των δυσλιπιδαιμιών; 🎙️ Ε. Λυμπερόπουλος | Χ. Μηλιώνης 👨‍⚕️ Προεδρείο: Φ. Μπάρκας 🔗 Εγγραφή: bit.ly/has-lipids202 #Lipids #Cardiology #HAS #EAS #Webinar

000

Fotios Barkas @fotiosbarkas.bsky.social · 09/10/2025

Evidence-based, scalable & practical — a path to change the #ASCVD trajectory.

100

Fotios Barkas @fotiosbarkas.bsky.social · 09/10/2025

Keypoints: ✅ Start early with potent oral combination therapy in high-risk or #ASCVD patients. ✅ Escalate to triple therapy (PCSK9-targeted agents or bempedoic acid) if not at target. ✅ Follow-up, adherence & optimization are key.

110

Fotios Barkas @fotiosbarkas.bsky.social · 09/10/2025

👉 doi.org/10.1093/eurheartj/eh...

100

Fotios Barkas @fotiosbarkas.bsky.social · 09/10/2025

Let’s fight back years of inertia in #lipid management by shifting from reactive “treat-and-wait” care to a proactive “Fire-and-Forget” approach — ensuring early, potent & sustained #LDL-C reduction! Delighted to share our new paper published in the European Heart Journal.

101

Fotios Barkas @fotiosbarkas.bsky.social · 02/10/2025

🚀 Big win for #ASCVD Prevention! The VESALIUS-CV Phase 3 trial fullfilled its primary endpoints: #evolocumab significantly reduced CVD events in high-risk patients without prior AMI or stroke. 💥💓 This is a major leap forward for primary prevention! zurl.co/SPJSp

prnewswire.com

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha®...

000

Fotios Barkas @fotiosbarkas.bsky.social · 09/08/2025

👏 Well done Nikolaos - Gavriil Kolios, who is one of my PhD Students, and the rest of the team George Ntaios H Milionis #Stroke #ACS #LipidLowering #cholesterol

000

Fotios Barkas @fotiosbarkas.bsky.social · 09/08/2025

👌 We know what to do after acute #coronary events 🤔 But what about stroke 🧠, the leading cause of #disability worldwide? 🧐 What’s the evidence 📚, which drugs 💊, and how low to go 📉? Enjoy 👇 www.thieme-connect.com/products/ejo...

130

Fotios Barkas @fotiosbarkas.bsky.social · 21/07/2025

🚨 Just out in the American Journal of Preventive Cardiology! Our latest review on the atheroprotective power of #SGLT2 inhibitors 💥 From 🧠 #stroke to #CAD & #PAD — SGLT2i are changing the game in #CVD prevention! Read it here! doi.org/10.1016/j.aj...

121

Fotios Barkas @fotiosbarkas.bsky.social · 17/06/2025

📖 Read the full paper here: 🔗 www.jacc.org/doi/10.1016/... 👏 Huge credit to all INTERASPIRE Investigators for this global contribution to cardiovascular prevention! #LipoproteinA #Lp_a #CVDPrevention #CardioTwitter #Lipidology #JACC #GlobalHealth

000

Fotios Barkas @fotiosbarkas.bsky.social · 17/06/2025

4️⃣ Most patients with high Lp(a) also had poorly controlled traditional risk factors. 📈 In regions lacking access to novel therapies, risk factor management must be improved several fold to offset Lp(a)-related residual risk.

100

Fotios Barkas @fotiosbarkas.bsky.social · 17/06/2025

3️⃣ Traditional lipids don’t predict Lp(a). LDL-C, non–HDL-C, and ApoB did not correlate with Lp(a) across most of its range. ✅ Bottom line: Measure Lp(a) directly—don’t rely on traditional lipids.

100

Fotios Barkas @fotiosbarkas.bsky.social · 17/06/2025

2️⃣ Eligibility for emerging Lp(a)-lowering therapies: ▪️ 6.2% at ≥200 nmol/L ▪️ 13.0% at ≥150 nmol/L ⚠️ Marked variation across WHO regions and even between countries within the same region.

100

Fotios Barkas @fotiosbarkas.bsky.social · 17/06/2025

1️⃣ Median Lp(a): 32 nmol/L 👉 82.4% of patients were below the 125 nmol/L threshold typically linked to increased ASCVD risk. 🧠 Suggests that Lp(a)’s contribution to CHD may be more complex than previously assumed.

100

Fotios Barkas @fotiosbarkas.bsky.social · 17/06/2025

🚨 Recently in @jaccjournals.bsky.social Key findings from the INTERASPIRE study on Lp(a) in 3,928 CHD patients across 13 countries 🌍 A 🧵 on what we found & what it means for future Lp(a)-lowering therapies:

120

Fotios Barkas @fotiosbarkas.bsky.social · 07/06/2025

🔜 See you next year—and don’t forget: 📍 December 2025 in Athens: Panhellenic Congress of HAS Working Groups 📍 May 2026 in Athens: EAS Congress

000

Fotios Barkas @fotiosbarkas.bsky.social · 07/06/2025

🎓 And just like that, our Summer School has come to an end! A heartfelt THANK YOU to all our amazing speakers and the engaged scholars who enriched the sessions with their questions and insights! 🙌 What a truly fruitful and inspiring experience! #Dyslipidemia #SummerSchool #HAS2025 #EAS #Lipids

100

Fotios Barkas @fotiosbarkas.bsky.social · 06/06/2025

🎉 The HAS Summer School has just kicked off!! 🧑‍🎓Time to dive deep into #lipoprotein metabolism with Prof Alexandros Tselepis and the epidemiology of secondary #dyslipidemias with Prof Demosthenes Panagiotakos! #HellenicAtherosclerosisSociety #HAS2025

001

Fotios Barkas @fotiosbarkas.bsky.social · 02/06/2025

🚨 Don’t miss this must-attend webinar! 🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection 🎙️ Keynote: Prof. Daniel Gaudet 📅 Wednesday, June 4, 2025 🕕 17:00 CET 💻 Online | Registration required 🔗 Reserve your spot now! Registration link below!

100

Fotios Barkas @fotiosbarkas.bsky.social · 31/05/2025

🎉 The 1st Pan-Cypriot Atherosclerosis Congress 🇨🇾 concluded with great success! A flawlessly organized event with high-level scientific content and warm hospitality. Representing the Hellenic Atherosclerosis Society 🇬🇷, we extend a big thank you to our colleagues in Cyprus!

101

Fotios Barkas @fotiosbarkas.bsky.social · 31/05/2025

A deep dive into secondary causes of #dyslipidemia, interactive sessions & the latest in #CardiovascularPrevention in a closed meeting with chosen scholars from #Greece and #Cyprus!💡 #Atherosclerosis #Syros2025 #MedicalEducation #Lipids #SummerSchool #ConferreMedConnect

010

Fotios Barkas @fotiosbarkas.bsky.social · 31/05/2025

🚨 Coming up: 18th Summer School of the Hellenic Atherosclerosis Society 🗓 June 6–7, 2025 | 📍Syros, Greece 🇬🇷

101

Fotios Barkas @fotiosbarkas.bsky.social · 22/05/2025

How you can get a grant? Tips from the best! Judith Sluimer Keith Channon New #AtheroTalk podcast now available! Live from #EASCONGRESS2025!! ENJOY! 👇👇👇👇👇👇👇👇👇👇🤔 open.spotify.com/episode/4ngq...

open.spotify.com

E14 LIVE from EAS 2025: Behind the Grant Application with Judith Sluimer & Keith Channon

AtheroTalk · Episode

000

Fotios Barkas @fotiosbarkas.bsky.social · 06/05/2025

What does EAS Young Fellows Programm mean?? It means SCIENCE, PASSION, FRIENDSHIP & a touch of ART — all in one squad! Loving the energy at #EASCongress2025 #EASYoungFellows #MyEAS2025 #AtheroTalk

062

Fotios Barkas @fotiosbarkas.bsky.social · 06/05/2025

We are waiting for you at the EAS Stage!! Social media and the physician: What can we harness? A powerful reminder of the digital tools at our fingertips to educate, connect, and inspire! #EAS2025 #EASCongress2025 #EASSoMe

020

Fotios Barkas @fotiosbarkas.bsky.social · 06/05/2025

We’ve just kicked off the E-HEALTH, AI AND BIG DATA workshop at #EAS2025 — where cutting-edge digital health meets clinical impact! #EASCongress2025 #EASSoMe

010

Fotios Barkas @fotiosbarkas.bsky.social · 06/05/2025

As Prof Ridker said at the EAS President's dinner last night: 'Science matters, truth matters, family matters, patients matter, friends matter…' This is exactly what EAS stands for! Passion. Purpose. People. #EAS2025 #EASCongress2025 #EASSoMe

000

Reposted by Fotios Barkas

Alexander Bartelt @barteltlab.bsky.social · 06/05/2025

EAS President’s dinner at @eassociety.bsky.social in Glasgow 🏴󠁧󠁢󠁳󠁣󠁴󠁿 with @lgamon.bsky.social et al.

1152